Login to Your Account

Vidaza Doubles Two-Year Survival In MDS Patients

By Jennifer Boggs

Friday, August 3, 2007
After taking a hit last week on news of an anticipated delay with cancer drug satraplatin, shares of Pharmion Corp. gained back ground - and then some - after reporting Phase III data showing that Vidaza, its myelodysplastic syndromes drug, extended overall survival by 74 percent in higher-risk MDS patients. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription